| Literature DB >> 25724648 |
Stephanie A Planque1, Yasuhiro Nishiyama1, Sari Sonoda1, Yan Lin2, Hiroaki Taguchi1, Mariko Hara1, Steven Kolodziej1, Yukie Mitsuda1, Veronica Gonzalez2, Hameetha B R Sait2, Ken-ichiro Fukuchi3, Richard J Massey4, Robert P Friedland5, Brian O'Nuallain6, Einar M Sigurdsson7, Sudhir Paul8.
Abstract
Classical immunization methods do not generate catalytic antibodies (catabodies), but recent findings suggest that the innate antibody repertoire is a rich catabody source. We describe the specificity and amyloid β (Aβ)-clearing effect of a catabody construct engineered from innate immunity principles. The catabody recognized the Aβ C terminus noncovalently and hydrolyzed Aβ rapidly, with no reactivity to the Aβ precursor protein, transthyretin amyloid aggregates, or irrelevant proteins containing the catabody-sensitive Aβ dipeptide unit. The catabody dissolved preformed Aβ aggregates and inhibited Aβ aggregation more potently than an Aβ-binding IgG. Intravenous catabody treatment reduced brain Aβ deposits in a mouse Alzheimer disease model without inducing microgliosis or microhemorrhages. Specific Aβ hydrolysis appears to be an innate immune function that could be applied for therapeutic Aβ removal.Entities:
Keywords: Alzheimer Disease; Amyloid-β (Abeta); Antibody Engineering; Catalytic Antibodies; Enzyme Catalysis; Immunotherapy; Innate Immunity; Light Chain Variable Domain; Neurotoxicity
Mesh:
Substances:
Year: 2015 PMID: 25724648 PMCID: PMC4400338 DOI: 10.1074/jbc.M115.641738
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157